STAGE IIIA HEPATOCELLULAR CARCINOMA AJCC V8
Clinical trials for STAGE IIIA HEPATOCELLULAR CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IIIA HEPATOCELLULAR CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IIIA HEPATOCELLULAR CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare liver cancer: Triple-Drug attack shows promise
Disease control Recruiting nowThis study tests a combination of three drugs—nivolumab (an immunotherapy), fluorouracil (chemotherapy), and interferon alpha 2b (immune booster)—in people with a rare type of liver cancer called fibrolamellar carcinoma that cannot be surgically removed. The goal is to see if the…
Matched conditions: STAGE IIIA HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 01:02 UTC
-
Liver cancer hope: combo therapy may boost survival after first treatment fails
Disease control Recruiting nowThis study is for people with advanced liver cancer that cannot be removed by surgery and has gotten worse after initial treatment with atezolizumab plus bevacizumab. Researchers want to see if adding another immunotherapy drug (atezolizumab) to a standard targeted therapy pill (…
Matched conditions: STAGE IIIA HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated May 17, 2026 01:01 UTC
-
New hope for advanced liver cancer: immune drugs after radiation show promise
Disease control Recruiting nowThis study is for people with advanced liver cancer that has spread. It tests whether giving two immune-boosting drugs (durvalumab with or without tremelimumab) after a short course of radiation can help shrink tumors. About 21 participants will receive radiation followed by the …
Matched conditions: STAGE IIIA HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Mary Feng, MD • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
Tailor-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors. The goal is to see if this combination is safe and helps the immune system fight cancer more effectively. A…
Matched conditions: STAGE IIIA HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
Electric field device shows promise in taming advanced cancers
Disease control Recruiting nowThis early-phase study tests a wearable device that creates low-intensity electric fields (tumor treating fields) combined with either cabozantinib or a chemo-immunotherapy pair (nab-paclitaxel and atezolizumab) in people with advanced solid tumors in the abdomen or chest. The go…
Matched conditions: STAGE IIIA HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:46 UTC